STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for inoperable lung cancer
Disease control OngoingThis phase 2 trial tested adding bevacizumab to standard chemotherapy and radiation for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients. The goal was to see if the combination could improve tumor c…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New drug cocktail targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC) that has stopped responding to standard treatments. The main goal is to find the safest dose and see if t…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Lung cancer radiation gets a precision boost: trial aims to hit tumors harder, spare healthy tissue
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Experimental combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a new two-drug combination (sapanisertib and osimertinib) in 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatment. The main goal is to find the safest dose and identify side effects. This is …
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC